Original Research
Published on 22 Oct 2024
Safety and efficacy of DEB-TACE in combination with lenvatinib and camrelizumab for the treatment of unresectable hepatocellular carcinoma (uHCC): a two-centre retrospective study
in Cancer Immunity and Immunotherapy
- 1,788 views